Biocryst Pharmaceuticals Inc (BCRX) Hedge Fund & Institutional Holdings (Q2 2026)

BCRX ranks #1978 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

319 institutions disclose a position in BCRX, but none treat it as a major bet — even TCG Crossover Management, LLC, its most concentrated holder, allocates just 2.6% of its own portfolio to it.

California State Teachers Retirement System has added to its BCRX position for two straight quarters, increasing it by $249.7M to reach $251.2M today.

Kynam Capital Management, LP has trimmed its BCRX position for two straight quarters, cutting it by $47.8M while still holding $25.2M.

BCRX is up 2.5% today, and institutions have been net buyers of $288.8M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

BCRX reported a net loss of $384.7M over the trailing twelve months.

• Not yet profitable — net loss of $384.7M over the trailing twelve months
• Revenue declined 4.4% year over year
• Net income declined year over year, from -$35.7M to -$384.7M
• Generated $347.4M in positive operating cash flow
• Current ratio of 2.06x — enough short-term assets to cover short-term liabilities